Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Investigate Long-term Pulmonary and Extrapulmonary Effects of COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04581135
Recruitment Status : Completed
First Posted : October 9, 2020
Last Update Posted : June 1, 2022
Sponsor:
Information provided by (Responsible Party):
University Hospital Inselspital, Berne

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Prospective Observational Swiss Cohort Study to Investigate Long-term Pulmonary and Extrapulmonary Effects of COVID-19.

Condition or disease Intervention/treatment
COVID-19 Other: COVID-19

Detailed Description:
COVID-19 is a coronavirus induced viral pneumonia leading to Acute Respiratory Distress Syndrome. Previous coronavirus infections (SARS and MERS) led to pulmonary fibrosis in up to 30%. Prospective evaluation of lung abnormalities and pulmonary fibrosis after COVID-19 infection is crucial as novel treatments against lung fibrosis of different etiologies are available. No data on pulmonary longterm effects in COVID-19 survivors are currently available. The nation-wide Swiss COVID-19 lung group establishes a meticulously characterized prospective cohort study on pulmonary long-term sequela of patients living in Switzerland.
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational [Patient Registry]
Actual Enrollment : 620 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 36 Months
Official Title: Prospective Observational Cohort Study to Investigate Long-term Pulmonary and Extrapulmonary Effects of COVID-19
Actual Study Start Date : May 1, 2020
Actual Primary Completion Date : January 30, 2022
Actual Study Completion Date : January 30, 2022

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
COVID-19 Lung
COVID-19 survivors in Switzerland
 Other: COVID-19
Research project in which biological material is sampled and health-related personal data are collected and used for further research. Coded data are used.
Other Names:
  • Sampling biological material
  • Collection of health-related personal data


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Pulmonary follow-up sequelae in patients after COVID-19 [ Time Frame: 36 months ]
    Number of patients with the long-term pulmonary complications by measuring lung function, exercise testing and radiological Imaging

  2. Evaluation of risk factors for adverse Outcome after COVID-19 [ Time Frame: 36 months ]
    Number of patients with risk factors including comorbidities and other cofactors and correlate them to adverse outcome in patients after COVID-19


Secondary Outcome Measures :
  1. Compare the functional Pulmonary outcome of COVID-19 disease [ Time Frame: 36 months ]
    Compare pulmonary function measurements between mild and moderate to severe and critical COVID-19 disease

  2. Compare the radiological Pulmonary outcome of COVID-19 disease [ Time Frame: 36 months ]
    Compare imaging measurements between mild and moderate to severe and critical COVID-19 disease

  3. Quality of Life after COVID-19 [ Time Frame: 36 months ]
    Compare Quality of Life questionnaires between mild and moderate to severe and critical COVID-19 disease

  4. Physical performance after COVID-19 using Clinical Frailty Scale [ Time Frame: 36 months ]
    To observe and compare the physical performance after COVID-19 via the Clinical Frailty Scale between mild and moderate to severe and critical COVID-19 disease

  5. Physical performance after COVID-19 using frailty assessment tests [ Time Frame: 36 months ]
    To observe and compare the physical performance after COVID-19 via frailty assessment tests between mild and moderate to severe and critical COVID-19 disease

  6. Microbiota and COVID-19 [ Time Frame: 36 months ]
    Number of patients with changes in microbiota in response to COVID-19 by microbiota analysis of sputa, bronchoalveolar lavage and swaps


Biospecimen Retention:   Samples Without DNA
Coded biological material

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients included are survivors of COVID-19.
Criteria

Inclusion Criteria:

  • Signed written informed consent.
  • All adult patients with COVID-19 over 18 years.

Exclusion Criteria:

  • Severe mental or physical disability precluding informed consent or compliance with the protocol for prospective data collection.
  • Pregnancy.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04581135


Locations
Layout table for location information
Switzerland
St. Claraspital AG - Department of Pulmonary Medicine
Basel, Switzerland, 4002
Universtiy Hospital Bern (Inselspital), Department of Pulmonary Medicine - Lead Center
Bern, Switzerland, 3010
University and Hospital of Fribourg
Fribourg, Switzerland, 1708
Hôpitaux Universitaires de Genève - Service de Pneumologie
Genève, Switzerland, 1211
CHUV - Service de Pneumologie
Lausanne, Switzerland, 1011
Clinica Moncucco
Lugano, Switzerland, 6900
Hôpital du Valais - Service de Pneumologie
Sion, Switzerland, 1950
Kantonspital St. Gallen - Klinik für Pneumologie und Schlafmedizin Lungenzentrum
St. Gallen, Switzerland, 9007
Universitätsspital Zürich - Klinik für Pneumologie
Zürich, Switzerland, 8091
Sponsors and Collaborators
University Hospital Inselspital, Berne
Investigators
Layout table for investigator information
Principal Investigator: Manuela Funke-Chambour, MD University Hospital Bern, Department of Pulmonary Medicine - Lead Center
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: University Hospital Inselspital, Berne
ClinicalTrials.gov Identifier: NCT04581135    
Other Study ID Numbers: 2020-00799
First Posted: October 9, 2020    Key Record Dates
Last Update Posted: June 1, 2022
Last Verified: May 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University Hospital Inselspital, Berne:
COVID-19
Coronavirus infection
Lung abnormalities
 Radiological abnormalities
ARDS
Quality of Life
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
 Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases